Table 1.
The imaging summarization of autoimmune GFAP astrocytopathy patients.
| Fang et al. (1) | Flanagan et al. (10) | Dubey et al. (11) | Iorio et al. (12) | Long et al. (13) | Yang et al. (14) | Kimura et al. (15) | Fang et al. (16) | Gravier et al. (17) | Liao et al. (18) | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Brain MRI | |||||||||||
| Hyperintense lesions on T2WI/FLAIR | 9/12 (75%) | 18/32 (56%) | NA | 10/22 (45%) | 8/19 (42.1%) | 9/10 (90%) | 9/14 (64%) | 30/35 (85.7%) | 20/39 (51.3%) | 13/15 (86.6%) | 126/198 (63.6%) |
| Linear perivascular radial enhancement | 6/12 (50%) | 17/32 (53%) | 36/71 (51%) | NA | 8/19 (42.1%) | 4/10 (40%) | 4/9 (44.4%) | 3/35 (8.5%) | 12/38 (31.6%) | 12/15 (80%) | 102/241 (42.3%) |
| Leptomeningeal enhancement | 4/12 (33%) | 7/32 (22%) | NA | NA | NA | NA | 3/9 (33.3%) | 6/35 (17.1%) | 10/38 (26.3%) | 12/15 (80%) | 42/141 (29.8%) |
| RESLES | NA | NA | NA | NA | NA | NA | NA | NA | 4/39 (10.3%) | NA | 4/39 (10.3%) |
| Spinal MRI | |||||||||||
| Longitudinally extensive T2 hyperintensity | 5/7 (71%) | 6/8 (75%) | NA | 3/9 (33%) | 11/16 (68.8%) | 6/9 (66.7%) | NA | 5/35 (14.3%) | 9/11 (81.2%) | 5/15 (33.3%) | 50/110 (45.5%) |
| Intramedullary enhancement | NA | NA | NA | NA | NA | NA | 1/7 (14%) | 3/35 (8.5%) | 4/11 (36.4%) | 7/15 (46.7%) | 15/68 (22.1%) |
| Enhancement of medullary cone surface | NA | NA | NA | NA | NA | NA | 5/7 (71%) | 3/35 (8.5%) | 4/11 (36.4%) | 9/15 (60%) | 21/68 (32.3%) |
GFAP, glial fibrillary acidic protein; MRI, magnetic resonance imaging; NA, not available; FLAIR, fluid-attenuated inversion-recovery sequency; RESLES, reversible splenial lesion syndrome.